Clinical trial
Gene Therapy for Prostate Cancer That Returns After Radiation Therapy
NCT00110526 · Simon Hall, Other · Withdrawn
Key facts
| NCT number | NCT00110526 |
|---|---|
| Title | Gene Therapy for Prostate Cancer That Returns After Radiation Therapy |
| Official title | Phase I Trial of Adenovirus- Mediated IL-12 Gene Transduction in Patients With Radiorecurrent Prostate Cancer |
| Lead sponsor | Simon Hall, Other |
| Collaborators | U.S. Army Medical Research and Development Command U.S. Fed |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms, Neoplasm Recurrence, Local |
| Intervention type | Genetic |
| Interventions | Ad.hIL-12 |
| Enrollment | 0 |
| Start date | Apr 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 11, 2005 |
| Last update posted | Oct 24, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: